Tissue Regenix Group plc
Tissue Regenix Presents at Proactiveinvestors One2One Forum in Dublin
YORK, 29 October 2013 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the international regenerative medical devices company, announces that Antony Odell, Managing Director, will be presenting at the Proactiveinvestors One2One Investor Forum in Dublin this evening.
Antony will provide an update on Tissue Regenix' progress since opening its TRX Wound Care Inc. US operation, including the partnership with Community Tissue Services (CTS) to develop DermaPure™,its decellularised dermis wound care product. Tissue Regenix this month announced that the full trial results into the effectiveness of DermaPure™ in treating resistant, chronic wounds, have now been published in the peer reviewed journal - Wound Repair and Regeneration. The paper showed 60% of patients with chronic wounds were completely healed and patients treated saw an average 87% reduction in the size of their wounds.
Antony will also provide an update on progress in developing treatments within Tissue Regenix' TRX Cardiac and TRX Orthopaedics divisions.
The event will run from 5.45pm (6.00pm start) to 8:00pm and will be held at the Shelbourne Hotel, 27 St Stephen's Green, Dublin, 2 Ireland. The presentation will contain no new material information.
Further information and a link to register participation can be found at:
http://www.proactiveinvestors.co.uk/register/event_details/209
ENDS
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 207 6806550
Alistair Kellie
Andrew Adie
Andrew Jones
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.
